These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23485748)

  • 1. A new nanoconstruct for epidermal growth factor receptor-targeted photo-immunotherapy of ovarian cancer.
    Mir Y; Elrington SA; Hasan T
    Nanomedicine; 2013 Oct; 9(7):1114-22. PubMed ID: 23485748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor-targeted photosensitizer selectively inhibits EGFR signaling and induces targeted phototoxicity in ovarian cancer cells.
    Abu-Yousif AO; Moor AC; Zheng X; Savellano MD; Yu W; Selbo PK; Hasan T
    Cancer Lett; 2012 Aug; 321(2):120-7. PubMed ID: 22266098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer.
    van Driel PBAA; Boonstra MC; Slooter MD; Heukers R; Stammes MA; Snoeks TJA; de Bruijn HS; van Diest PJ; Vahrmeijer AL; van Bergen En Henegouwen PMP; van de Velde CJH; Löwik CWGM; Robinson DJ; Oliveira S
    J Control Release; 2016 May; 229():93-105. PubMed ID: 26988602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR-targeted liposomal nanohybrid cerasomes: theranostic function and immune checkpoint inhibition in a mouse model of colorectal cancer.
    Li Y; Du Y; Liang X; Sun T; Xue H; Tian J; Jin Z
    Nanoscale; 2018 Sep; 10(35):16738-16749. PubMed ID: 30156250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo.
    del Carmen MG; Rizvi I; Chang Y; Moor AC; Oliva E; Sherwood M; Pogue B; Hasan T
    J Natl Cancer Inst; 2005 Oct; 97(20):1516-24. PubMed ID: 16234565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-targeting and direct immunotargeting of liposomal drug carriers to ovarian carcinoma.
    Lehtinen J; Raki M; Bergström KA; Uutela P; Lehtinen K; Hiltunen A; Pikkarainen J; Liang H; Pitkänen S; Määttä AM; Ketola RA; Yliperttula M; Wirth T; Urtti A
    PLoS One; 2012; 7(7):e41410. PubMed ID: 22844475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Light-Controlled Delivery of Monoclonal Antibodies for Targeted Photoinactivation of Ki-67.
    Wang S; Hüttmann G; Zhang Z; Vogel A; Birngruber R; Tangutoori S; Hasan T; Rahmanzadeh R
    Mol Pharm; 2015 Sep; 12(9):3272-81. PubMed ID: 26226545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Physiochemical,
    Shah N; Soma SR; Quaye MB; Mahmoud D; Ahmed S; Malkoochi A; Obaid G
    ACS Appl Bio Mater; 2024 Jul; 7(7):4427-4441. PubMed ID: 38934648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Combination of Visudyne and a Lipid-anchored Liposomal Formulation of Benzoporphyrin Derivative Enhances Photodynamic Therapy Efficacy in a 3D Model for Ovarian Cancer.
    Rizvi I; Nath S; Obaid G; Ruhi MK; Moore K; Bano S; Kessel D; Hasan T
    Photochem Photobiol; 2019 Jan; 95(1):419-429. PubMed ID: 30499113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Verteporfin mediated sequence dependent combination therapy against ovarian cancer cell line.
    Erdem SS; Obeidin VA; Yigitbasi T; Tumer SS; Yigit P
    J Photochem Photobiol B; 2018 Jun; 183():266-274. PubMed ID: 29747146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Photodynamic therapy of squamous cell carcinoma. An evaluation of a new photosensitizing agent, benzoporphyrin derivative and new photoimmunoconjugate.
    Hemming AW; Davis NL; Dubois B; Quenville NF; Finley RJ
    Surg Oncol; 1993; 2(3):187-96. PubMed ID: 8252208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab-labeled liposomes containing near-infrared probe for in vivo imaging.
    Portnoy E; Lecht S; Lazarovici P; Danino D; Magdassi S
    Nanomedicine; 2011 Aug; 7(4):480-8. PubMed ID: 21272665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using cellular mechanisms to develop effective combinations of photodynamic therapy and targeted therapies.
    Hasan T
    J Natl Compr Canc Netw; 2012 Oct; 10 Suppl 2():S23-6. PubMed ID: 23055209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivo in mice.
    Hu Z; Rao B; Chen S; Duanmu J
    BMC Cancer; 2010 May; 10():235. PubMed ID: 20504328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photodynamic therapy activated signaling from epidermal growth factor receptor and STAT3: Targeting survival pathways to increase PDT efficacy in ovarian and lung cancer.
    Edmonds C; Hagan S; Gallagher-Colombo SM; Busch TM; Cengel KA
    Cancer Biol Ther; 2012 Dec; 13(14):1463-70. PubMed ID: 22986230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained ERK [corrected] inhibition by EGFR targeting therapies is a predictive factor for synergistic cytotoxicity with PDT as neoadjuvant therapy.
    Weyergang A; Selbo PK; Berg K
    Biochim Biophys Acta; 2013 Mar; 1830(3):2659-70. PubMed ID: 23671927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor (EGFR) density may not be the only determinant for the efficacy of EGFR-targeted photoimmunotherapy in human head and neck cancer cell lines.
    Peng W; de Bruijn HS; Farrell E; Sioud M; Mashayekhi V; Oliveira S; van Dam GM; Roodenburg JLN; Witjes MJH; Robinson DJ
    Lasers Surg Med; 2018 Jul; 50(5):513-522. PubMed ID: 29777587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photodynamic tumor eradication with a novel targetable photosensitizer: strong vascular effects and dependence on treatment repetition versus potentiation.
    Savellano MD; Owusu-Brackett N; Son J; Ganga T; Leung NL; Savellano DH
    Photochem Photobiol; 2013; 89(3):687-97. PubMed ID: 23145766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells.
    Wang Y; Zhou J; Qiu L; Wang X; Chen L; Liu T; Di W
    Biomaterials; 2014 May; 35(14):4297-309. PubMed ID: 24565522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Actively targeted cetuximab conjugated gamma-poly(glutamic acid)-docetaxel nanomedicines for epidermal growth factor receptor over expressing colon cancer cells.
    Maya S; Sarmento B; Lakshmanan VK; Menon D; Jayakumar R
    J Biomed Nanotechnol; 2014 Aug; 10(8):1416-28. PubMed ID: 25016642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.